Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Fairview Ridges Hospital — Burnsville, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Cambridge Medical Center — Cambridge, Minnesota
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health - Baxter Clinic — Baxter, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Minnesota: - Avera Cancer Institute- Marshall — Marshall, Minnesota
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Minnesota: - Minnesota Oncology Hematology, PA — Burnsville, Minnesota
- Allina Health Cancer institute — Coon Rapids, Minnesota
- Minnesota Oncology Hematology, PA — Coon Rapids, Minnesota
- M Health Fairview Cancer Clinic-Edina — Edina, Minnesota
- Minnesota Oncology Hematology, PA — Edina, Minnesota
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Minnesota: - Clinical Study Site — Saint Louis Park, Minnesota
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Minnesota: - Minnesota Oncology Hematology — Maple Grove, Minnesota
- Mayo Clinic (Minnesota) — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Industry
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…
Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in Minnesota: - Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Minnesota: - Scri Minnesota Oncology Hematology, P.A. /ID# 275149 — Minneapolis, Minnesota
- Mayo Clinic-Rochester /ID# 273508 — Rochester, Minnesota
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Minnesota: - M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, two-part trial in participants with FAP.
Sponsor: Recursion Pharmaceuticals Inc.
NCT ID: NCT05552755
Sites in Minnesota: - Mayo Clinic - Rochester — Rochester, Minnesota
Phase 2 Recruiting Industry
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Sponsor: AstraZeneca
NCT ID: NCT06792695
Sites in Minnesota: - Research Site — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT06948448
Sites in Minnesota: - May Clinic Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Minnesota: - Masonic Cancer Center University of Minnesota — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd…
Sponsor: GI Innovation, Inc.
NCT ID: NCT05824975
Sites in Minnesota: - Mayo Clinic in Minnesota — Rochester, Minnesota
Phase 2 Recruiting NIH
This open-label phase II trial tests how well TPST-1495 works in reducing the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is an inherited condition in which numerous polyps (grow…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06557733
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Minnesota: - Exelixis Clinical Site #68 — Rochester, Minnesota
Phase 1 Recruiting Industry
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06131840
Sites in Minnesota: - Mayo Clinic Cancer Center — Rochester, Minnesota
- Mayo Clinic — Rochester, Minnesota
Phase 1 Recruiting Industry
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …
Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in Minnesota: - Mayo Clinic - Rochester — Rochester, Minnesota
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and …
Sponsor: Xencor, Inc.
NCT ID: NCT05433142
Sites in Minnesota: - Xencor Investigative Site — Rochester, Minnesota
Phase 1 Recruiting Industry
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Sponsor: Incyte Corporation
NCT ID: NCT06179160
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 1 Recruiting Industry
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itsel…
Sponsor: Kumquat Biosciences Inc.
NCT ID: NCT06720987
Sites in Minnesota: - Mayo Clinic, Rochester — Rochester, Minnesota